Evaluation of The Cost Saving Potential of Introducing Benepali®, An Etanercept Biosimilar, For The Treatment of All Licensed Adult Etanercept Indications In Four Regions In Germany
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1089
https://www.valueinhealthjournal.com/article/S1098-3015(16)32455-X/fulltext
Title :
Evaluation of The Cost Saving Potential of Introducing Benepali®, An Etanercept Biosimilar, For The Treatment of All Licensed Adult Etanercept Indications In Four Regions In Germany
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32455-X&doi=10.1016/j.jval.2016.09.1089
First page :
A534
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1019